Opioid maker Insys Therapeutics has agreed to a $225 million global resolution to settle the government’s separate criminal and civil investigations concerning deceptive marketing and distribution of its opioid drug, Subsys.
In the aftermath of the settlement, Insys has filed for bankruptcy protection.
